Format

Send to

Choose Destination
Leuk Lymphoma. 2015;56(10):2803-11. doi: 10.3109/10428194.2015.1016933. Epub 2015 Mar 30.

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.

Author information

1
a Groupe d'analyse , Ltée, Montréal , Québec , Canada.
2
b Analysis Group, Inc ., Boston , MA , USA.
3
c Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA.
4
d Mayo Clinic Cancer Center , Scottsdale , AZ , USA.

Abstract

Iron chelation therapies (ICTs) can help eliminate iron surplus in erythrocyte transfusion-dependent (TD) patients with myelofibrosis (MF). The study assessed adjusted incidence rate ratios (aIRRs) of MF-related complications and resource utilization (RU) and adjusted mean monthly inpatient cost differences in patients with TD MF treated with versus without ICT (ICT+ vs. ICT-) using data from two healthcare claims databases. Patients with ≥ 2 MF International Classification of Diseases, 9th Revision (ICD-9) diagnosis codes ≥ 30 days apart were included. Among 571 patients with TD MF, 103 (18%) were ICT+ and 468 (82%) were ICT-. ICT+ patients had lower rates of thrombocytopenia (aIRR: 0.55; p < 0.001), pancytopenia (0.53; p < 0.001), emergency room visits (0.84 [95% confidence interval: 0.74-0.96]) and inpatient stays (0.75 [0.64-0.87]), but higher rates of outpatient visits (1.21 [1.18-1.23]). Adjusted mean complication-related inpatient cost difference per month was lower in ICT+ patients (-$1804 [$570]; p = 0.004). ICT+ patients had significantly lower rates of acute care, but higher rates of outpatient care.

KEYWORDS:

Myelofibrosis; economic cost; iron chelation therapy; medical resource utilization; transfusion dependent

PMID:
25676036
DOI:
10.3109/10428194.2015.1016933
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center